Prevalence and related factors of DR in patients with type 2 diabetes mellitus in the southern medical treatment combination of Chaoyang District, Beijing
- VernacularTitle:北京市朝阳区南部医联体2型糖尿病患者DR患病率及相关因素分析
- Author:
Hong-Xing Wang
1
Author Information
- Publication Type:Journal Article
- Keywords: diabetic retinopathy; prevalence; risk factors; medical treatment combination
- From: International Eye Science 2019;19(1):142-147
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To understand the prevalence of diabetic retinopathy(DR)in patients with type 2 diabetes mellitus in the southern medical treatment combination of Chaoyang District, Beijing, and to analyze the risk factors.
METHODS:A stratified cluster random sampling method was used to randomly select 840 residents aged 40 years and older who were diagnosed with type 2 diabetes mellitus as the target population for the survey from the residents health records of five Community Health Service Centers in the southern medical treatment combination of Chaoyang District, Beijing from November 2016 to November 2017. General patient data, physical examination, blood test results were collected, and all patients underwent dilated fundus examination. The prevalence of DR was calculated and Logistic regression was used to analyze DR risk factors.
RESULTS: The prevalence of diabetic retinopathy in patients with type 2 diabetes mellitus in the southern medical treatment combination of Chaoyang District, Beijing was 35.7%, among which the prevalence of mild, moderate and severe nonproliferative and proliferative diseases was 68.3%, 12.3%, 5.0% and 14.3%, respectively. Age, duration, insulin use, HbA1c and diabetic foot were independent risk factors for DR.
CONCLUSION: The prevalence of DR in patients with type 2 diabetes is higher in the area. When community doctors regularly follow up on diabetic patients, they should not only urge patients to strictly control blood sugar, regularly detect HbA1c, but also pay special attention to younger patients, patients with long course, patients with insulin use and patients with diabetic foot.
